Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0004135 (
ATM
)
13,001
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Recent studies have linked constitutive telomere length (TL) to aging-related diseases including cancer at different sites.
ATM
participates in the signaling of telomere erosion, and inherited mutations in
ATM
have been associated with increased risk of cancer, particularly breast cancer. The goal of this study was to investigate whether carriage of an
ATM
mutation and TL interplay to modify cancer risk in
ataxia-telangiectasia
(
A-T
) families.The study population consisted of 284 heterozygous
ATM
mutation carriers (HetAT) and 174 non-carriers (non-HetAT) from 103
A-T
families. Forty-eight HetAT and 14 non-HetAT individuals had cancer, among them 25 HetAT and 6 non-HetAT were diagnosed after blood sample collection. We measured mean TL using a quantitative PCR assay and genotyped seven single-nucleotide polymorphisms (SNPs) recurrently associated with TL in large population-based studies.HetAT individuals were at increased risk of cancer (OR = 2.3, 95%CI = 1.2-4.4, P = 0.01), and particularly of breast cancer for women (OR = 2.9, 95%CI = 1.2-7.1, P = 0.02), in comparison to their non-HetAT relatives. HetAT individuals had longer telomeres than non-HetAT individuals (P = 0.0008) but TL was not associated with cancer risk, and no significant interaction was observed between
ATM
mutation status and TL. Furthermore, rs9257445 (
ZNF311
) was associated with TL in HetAT subjects and rs6060627 (BCL2L1) modified cancer risk in HetAT and non-HetAT women.Our findings suggest that carriage of an
ATM
mutation impacts on the age-related TL shortening and that TL per se is not related to cancer risk in
ATM
carriers. TL measurement alone is not a good marker for predicting cancer risk in
A-T
families.
...
PMID:Telomere length, ATM mutation status and cancer risk in Ataxia-Telangiectasia families. 2898 72